Moreover, a recent report from Novartis demonstrated that fibroblast growth factor receptor (FGFR)–driven cancers, such as many breast or prostate cancers, are inherently resistant to SHP099-like inhibitors (34), because rapid feedback activation of the FGFR causes increased recruitment and activation of SHP2. This evidence concerns the gene PTPN11 and cancer.